STOCK TITAN
  1. Home
  2. News
  3. AMLX

Amylyx Pharmaceuticals Inc - AMLX STOCK NEWS

Welcome to our dedicated news page for Amylyx Pharmaceuticals (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amylyx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amylyx Pharmaceuticals's position in the market.

News
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced the initiation of the ORION Phase 3 clinical trial of AMX0035 for the treatment of progressive supranuclear palsy (PSP). The trial will enroll approximately 600 participants in the largest PSP clinical trial to date, spanning across the U.S., Canada, Europe, and Japan. The primary efficacy endpoint will evaluate change in disease progression from baseline to Week 52, with topline results anticipated in 2-3 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
clinical trial
-
News
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced the publication of analyses performed on neuroinflammatory biomarkers from the Phase 2 CENTAUR trial. The post hoc analyses demonstrated a significant reduction in plasma concentrations of YKL-40 and CRP, but not CHIT1, over 24 weeks, with reductions observed as early as Week 12 in participants from the CENTAUR trial. The results suggest that YKL-40 could be a treatment-sensitive biomarker, and further analyses are planned in the ongoing Phase 3 PHOENIX trial to confirm these results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
-
News
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) granted stock options and restricted stock units to its new Chief Medical Officer, Dr. Camille L. Bedrosian. The Compensation Committee approved the grant effective November 27, 2023, consisting of non-qualified stock option awards to purchase up to 162,500 shares of the company's common stock and 58,333 RSUs under the 2023 Inducement Plan. The options have an exercise price of $12.93 per share, with a ten-year term and vesting over four years. The RSUs will vest in four installments on the first four anniversaries of the applicable vesting commencement date, subject to Dr. Bedrosian’s continued employment with Amylyx. The awards were granted as an inducement material to Dr. Bedrosian entering into employment with Amylyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
News
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced the appointment of Dr. Camille L. Bedrosian as Chief Medical Officer. Dr. Bedrosian brings nearly 30 years of leadership in clinical research and development, with experience at Ultragenyx, Alexion, and ARIAD Pharmaceuticals. She will lead global medical functions at Amylyx, focusing on addressing unmet medical needs for people with rare and serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
management
-
News
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (AMLYX) announced the presentation of new data on AMX0035 and AMX0114 for the potential treatment of ALS and other neurodegenerative diseases at the 34th International Symposium on ALS/MND. The abstracts detail studies on mortality-adjusted progression, ongoing and planned studies for AMX0035, development of a diagnostic biomarker for ALS, and strategies to enhance the palatability of the treatment. The Company aims to use the MAP model for the primary efficacy analysis in the Phase 3 PHOENIX trial with results expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
News
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (AMLYX) Co-CEOs to participate in the 6th Annual Evercore ISI HealthCONx Conference. The fireside chat will be held on Tuesday, November 28, 2023, at 2:10pm ET. A live webcast of the presentation can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
conferences
News
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) reported strong financial results for Q3 2023, with $102.7 million in product revenue, bringing total product revenue to $272.3 million in the first three full quarters of U.S. launch. Net income was $20.9 million, with cash, cash equivalents, and short-term investments of $355.0 million at September 30, 2023. The company also highlighted the progress of commercial launches of RELYVRIO® in the U.S. and ALBRIOZA™ in Canada, and the positive results of a post hoc survival analysis comparing the CENTAUR clinical trial to historical clinical trial control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.89%
Tags
earnings
-
News
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will report its Q3 2023 financial results on November 9, 2023. The senior management team will host a conference call and webcast at 8:00 a.m. ET to discuss the results. The conference call details can be found on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
conferences earnings
-
News
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposium
Rhea-AI Summary
Amylyx Pharmaceuticals announces upcoming presentation at Neuro2023 on the design of ORION, a Phase 3 clinical trial of AMX0035 in progressive supranuclear palsy (PSP)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
conferences clinical trial
News
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Rhea-AI Summary
Amylyx Pharmaceuticals receives initial negative opinion from CHMP for AMX0035 in the EU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Stock AMLX logo
Amylyx Pharmaceuticals Inc

Nasdaq:AMLX

AMLX Rankings

#4082 Ranked by Market Cap
#4813 Ranked by Stock Gains
N/A Ranked by Dividends

AMLX Stock Data

136.24M
50.94M
14.24%
104.79%
8.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cambridge

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.